Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
OtherBASIC SCIENCE INVESTIGATIONS

Human Biodistribution and Dosimetry of the D2/3 Agonist 11C-N-Propylnorapomorphine (11C-NPA) Determined from PET

Charles M. Laymon, N. Scott Mason, W. Gordon Frankle, Jonathan P. Carney, Brian J. Lopresti, Maralee Y. Litschge, Chester A. Mathis, James M. Mountz and Rajesh Narendran
Journal of Nuclear Medicine May 2009, 50 (5) 814-817; DOI: https://doi.org/10.2967/jnumed.108.058131
Charles M. Laymon
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
N. Scott Mason
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
W. Gordon Frankle
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jonathan P. Carney
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Brian J. Lopresti
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maralee Y. Litschge
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chester A. Mathis
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
James M. Mountz
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rajesh Narendran
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • Additional Files
  • FIGURE 1. 
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 1. 

    11C-NPA coronal PET image (hot metal scale) overlaid on attenuation image reconstructed from transmission data (gray scale) for male subject. PET data have been summed over first 4 scans and the image roughly represents activity distribution averaged over first 20 min after injection.

  • FIGURE 2. 
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 2. 

    Activity concentration, normalized by injected dose, in various organs as function of time.

Tables

  • Figures
  • Additional Files
    • View popup
    TABLE 1

    Research Subject Demographics

    Subject no.SexHeight (cm)Weight (kg)Age (y)
    1F1616922
    2F1686638
    3F1707339
    4M1808220
    5M1756424
    6M1808021
    • View popup
    TABLE 2

    Average Organ Residence Times

    OrganResidence time (s)
    Liver439.0
    Duodenum252.3
    Urinary bladder106.0
    Kidney97.6
    Lung89.9
    Brain77.2
    Cortical bone46.4
    Gallbladder33.3
    Upper large intestine30.4
    Red marrow25.0
    Lower large intestine17.9
    Heart13.5
    • View popup
    TABLE 3

    Absorbed Radiation Dose Normalized to Injected Dose (mSv/MBq)

    Dose from…
    Target organβPhotonTotalSD
    Adrenals5.12 × 10−43.29 × 10−33.80 × 10−35.50 × 10−4
    Brain3.65 × 10−31.83 × 10−35.48 × 10−34.89 × 10−4
    Breasts5.12 × 10−49.68 × 10−41.48 × 10−32.57 × 10−4
    Gallbladder wall1.99 × 10−28.26 × 10−32.81 × 10−21.08 × 10−2
    LLI wall4.46 × 10−33.16 × 10−37.62 × 10−31.03 × 10−3
    Small intestine1.99 × 10−24.97 × 10−32.48 × 10−23.98 × 10−3
    Stomach wall5.12 × 10−42.17 × 10−32.68 × 10−33.78 × 10−4
    ULI wall4.76 × 10−35.45 × 10−31.02 × 10−22.14 × 10−3
    Heart wall1.47 × 10−32.20 × 10−33.67 × 10−34.35 × 10−4
    Kidneys2.09 × 10−26.34 × 10−32.72 × 10−25.72 × 10−3
    Liver1.68 × 10−28.27 × 10−32.50 × 10−24.44 × 10−3
    Lungs6.24 × 10−32.30 × 10−38.54 × 10−32.07 × 10−3
    Muscle5.12 × 10−41.43 × 10−31.94 × 10−32.70 × 10−4
    Ovaries5.88 × 10−43.84 × 10−34.43 × 10−32.10 × 10−4
    Pancreas5.12 × 10−43.09 × 10−33.60 × 10−34.87 × 10−4
    Red marrow9.33 × 10−41.84 × 10−32.78 × 10−36.87 × 10−4
    Osteogenic cells2.39 × 10−31.44 × 10−33.83 × 10−39.23 × 10−4
    Skin5.12 × 10−47.75 × 10−41.29 × 10−32.16 × 10−4
    Spleen5.12 × 10−41.93 × 10−32.44 × 10−33.77 × 10−4
    Testes4.35 × 10−49.07 × 10−41.34 × 10−31.45 × 10−4
    Thymus5.12 × 10−41.17 × 10−31.68 × 10−33.03 × 10−4
    Thyroid5.12 × 10−47.66 × 10−41.28 × 10−32.29 × 10−4
    Urinary bladder wall1.82 × 10−26.71 × 10−32.49 × 10−26.28 × 10−3
    Uterus5.88 × 10−43.85 × 10−34.44 × 10−32.06 × 10−4
    Total body1.49 × 10−31.68 × 10−33.17 × 10−34.01 × 10−4
    • LLI wall = lower large intestine wall; ULI = upper large intestine wall.

    • The organ receiving the highest dose was the gallbladder wall. Final column lists standard deviation of total dose across subjects.

Additional Files

  • Figures
  • Tables
  • Supplemental Data

    Files in this Data Supplement:

    • Supplemental Table 1
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 50 (5)
Journal of Nuclear Medicine
Vol. 50, Issue 5
May 2009
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Supplemental Data
  • Supplemental Data
  • Supplemental Data
  • Supplemental Data
  • Supplemental Data
  • Supplemental Data
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Human Biodistribution and Dosimetry of the D2/3 Agonist 11C-N-Propylnorapomorphine (11C-NPA) Determined from PET
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Human Biodistribution and Dosimetry of the D2/3 Agonist 11C-N-Propylnorapomorphine (11C-NPA) Determined from PET
Charles M. Laymon, N. Scott Mason, W. Gordon Frankle, Jonathan P. Carney, Brian J. Lopresti, Maralee Y. Litschge, Chester A. Mathis, James M. Mountz, Rajesh Narendran
Journal of Nuclear Medicine May 2009, 50 (5) 814-817; DOI: 10.2967/jnumed.108.058131

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Human Biodistribution and Dosimetry of the D2/3 Agonist 11C-N-Propylnorapomorphine (11C-NPA) Determined from PET
Charles M. Laymon, N. Scott Mason, W. Gordon Frankle, Jonathan P. Carney, Brian J. Lopresti, Maralee Y. Litschge, Chester A. Mathis, James M. Mountz, Rajesh Narendran
Journal of Nuclear Medicine May 2009, 50 (5) 814-817; DOI: 10.2967/jnumed.108.058131
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • CONCLUSION
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF

Related Articles

  • This Month in JNM
  • PubMed
  • Google Scholar

Cited By...

  • 18F-MCL-524, an 18F-Labeled Dopamine D2 and D3 Receptor Agonist Sensitive to Dopamine: A Preliminary PET Study
  • Whole-Body Distribution and Radiation Dosimetry of 11C-(+)-PHNO, a D2/3 Agonist Ligand
  • Radiation Dosimetry and Biodistribution of the TSPO Ligand 11C-DPA-713 in Humans
  • Google Scholar

More in this TOC Section

  • Tumor Uptake of Anti-CD20 Fabs Depends on Tumor Perfusion
  • How Sensitive Is the Upper Gastrointestinal Tract to 90Y Radioembolization? A Histologic and Dosimetric Analysis in a Porcine Model
  • 11C-Methionine PET of Myocardial Inflammation in a Rat Model of Experimental Autoimmune Myocarditis
Show more Basic Science Investigations

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire